Tagged with TAP

Italy Octapharm’s Abramo Brandi, Managing Director of Italy and VP Africa, outlines the particularities of the plasma derivatives business in general and the Italian market in particular. He also explains the company’s new opportunities in Africa. … 60-70 percent of current Italian needs are covered self-sufficiently. In Italy plasma is for…

UK Keith Thompson, CEO of the Cell & Gene Therapy Catapult, one of a number of Catapult institutions in the UK designed to help commercialize innovative research, discusses strategy, funding, international collaboration and Brexit.     Most likely, the UK is the best environment for putting forward trials that are properly…

Brazil When combining the sheer size of Brazil – the fifth largest country in the world – with its tropical climate, its largely perfectible infrastructure, and the soaring importance of temperature sensitive biologicals, one understands the urgent need to develop solutions guaranteeing appropriate transport conditions in Brazil. “We may be vaguely…

Brazil Samuel Mauricio, vice-president for Brazil at Octapharma, one of the largest human protein manufacturers in the world, provides an insightful analysis of the Brazilian plasma market, demonstrating Octapharma’s remarkable willingness to further position itself as the partner of choice for the country’s public healthcare system. As the head of the…

Austria Barbara Rangetiner and Josef Weinberger of the Austrian affiliate of Octapharma, the largest privately owned human protein products manufacturer in the world, discuss the strategic significance of Austria to the group, the nation’s historical excellence in plasma and hematology, and recent upgrades to the affiliate’s manufacturing and fractionation capabilities Vienna…

Pharma Abramo Brandi, Octapharma Italy’s MD, discusses the challenges of the tender system in Italy and how he has grown the company year-on-year in the midst of a global economic crisis. What are some of your major achievements since becoming Managing Director of Octapharma Italy in 2008? I was asked to…

Pharma Galderma Italy was a founding European affiliate for the company and has seen incredible growth in the past two decades. Managing Director  Bernat Albinyana discusses the affiliate’s performance, its business organization and commitment to R&D, as well as its grand ambitions for the next few years. In 1986, Italy was…

generics The CEO of DefiLatina Healthcare reveals how a reliance on social security has seen the public health system struggle to meet the demands placed upon it, how her company´s vision is to partner with the regulatory authorities, helping to increase the country´s access to medicines and why they were voted…

Contract Manufacturing Lilly set up in Ireland three decades ago by purchasing a farm. In its early days, the operation produced intermediaries for small-molecule drugs. Nearby, Pfizer was manufacturing citric acid for soft drinks. The country was a fledgling industrial economy that was still mostly reliant on sectors like agriculture and fishing.…

Rottapharm Ireland Mr. Garrahy, can you please begin by introducing yourself and this production facility to our readers? I joined Rottapharm in 1998, when the organization decided to establish its Dublin production facility. Prior to that, I was a plant manager for Warner Lambert in Cork. When I took on this role,…

Octapharma Brazil Mr. Mauricio, you’ve mentioned that Brazil is a different kind of market for Octapharma, one strongly based on price, and that because of this it’s hard to add value. Could you delve a bit deeper and elaborate on this point? Before delving into the Brazilian market situation, it is important…

Octapharma Mexico Please can you give our readers a brief rundown of the major milestones and challenges that you have faced at Octapharma since becoming Managing Director? When Octapharma first came to Mexico in 1994, it was through a distribution agreement with a local company. Six years later in the year 2000…